Having identified LINGO2 and RBFOX1 as key genes that show conserved changes in our in vitro system as well as in human genetic and postmortem tissue data, we asked if targeting LINGO2 and RBFOX1 would lead to a rescue of disease phenotypes in APPV717I neurons, thereby establishing these genes as potential therapeutic targets in AD. This evidence concerns the gene RBFOX1 and Alzheimer disease.